The REFLECT Trial: A Randomized Evaluation oF the | Clinical Research Studies Listing

Recruiting

99 years or below

All

Phase 2

40 participants needed

1 Location

Brief description of study

This is a research study designed to look at the safety and effectiveness of the TriGUARD 3 cerebral embolic protection device in patients undergoing transcatheter aortic valve implantation (TAVI). The purpose of the study is to assess whether the TriGUARD 3 can prevent death, stroke, more subtle signs of brain injury, and/or silent brain injury as measured by a magnetic resonance imaging (MRI) study of the brain.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Cerebral Embolic Lesion
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 830258

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

The REFLECT Trial: A Randomized Evaluation oF the TriGuard HDH Cerebral Embolic Protection Device and the TriGUARD 3 Cerebral Embolic Protection Device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation

Brief description of study

Eligibility of study

Find a site

Interested in the study